Merit Medical Launches Torpedo Gelatin Foam for Embolization of Hypervascular Tumors

 

September 13, 2019—Merit Medical Systems, Inc. announced the commercial launch of the company’s Torpedo gelatin foam indicated for use in the embolization of hypervascular tumors. The Torpedo provides physicians with a preshaped gelatin foam loaded into a cartridge with an optional blunt stylet, removing the need for manual foam shaping and providing fast and easy attachment to the catheter for delivery.

According to the company, the Torpedo is easy to prepare and use, requiring only hydration with a 50:50 saline-to-contrast mixture. The product is available in two diameters (2.5 mm and 5 mm) and two lengths (10 mm and 20 mm) and is designed for use with a catheter with an inner diameter large enough to allow delivery of the Torpedo to the target vasculature via syringe injection. The gelatin foam in the Torpedo is biocompatible, hydrophilic, and resorbable.

The Torpedo device will save physicians time and improve material delivery with precision and predictability by eliminating manual cutting and shaping, stated Merit Medical.

In addition to the Torpedo, Merit’s embolization gelatin technology includes the EmboCube, which received FDA 510(k) clearance in November 2018. The EmboCube provides uniformly cut cubes of gelatin foam preloaded into a syringe. The device is designed to save time and avoid inconsistent particle sizes associated with manual preparation of gelatin foam sheets.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.